Vanda Pharmaceuticals Inc. - Common Stock (VNDA)

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

Vanda said it expects Bysanti to be available in the market in the third quarter of 2026.

This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December.

The company said that if approved, Bysanti could be available for sale in the U.S. this year.

Vanda (VNDA) Q4 2025 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion.

Investors head into the final trading session of 2025 with caution.

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a

The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025.

As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon?